SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 2 or 4 weeks. In people with asthma, CRSwNP and food allergy, a blood test for a substance called IgE must be ...
PALO ALTO, Calif. (KGO) -- Researchers at Stanford say a newly approved drug treatment could change the lives of millions of children with food allergies. While it's not a cure, they say it can ...
The U.S. Food and Drug Administration (FDA) has approved a medication for use in treating severe food allergies, and the agency says that this injection is the first of its kind. The drug, which has ...
About 20 million people in the U.S.—including four million children—have food allergies. Now, there's a new way to reduce their risk of severe allergic reactions. A study published in the New England ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new positive data from Stage 2 and Stage 3 of the National Institutes ...
CHICAGO (WLS) -- After the FDA approved a medication called Xolair to help lessen the severity of an accidental allergic reaction in people who are allergic to multiple foods, sufferers say they're ...
A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions, the U.S. Food and Drug Administration said Friday. Xolair, the brand name for the drug ...
A new study finds that the asthma medication Xolair may substantially reduce severe allergic reactions in people who have multiple food allergies and are accidentally exposed to those foods. Data ...
– Xolair is the only U.S. FDA-approved medicine to reduce allergic reactions in children and adults with one or more food allergies – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member ...
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate ...